Axonics® to Participate in the SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX) will participate in the virtual SVB Leerink Global Healthcare Conference on February 24, 2021, presenting at 11:20 a.m. Eastern Time. Axonics specializes in innovative implantable sacral neuromodulation devices that treat urinary and bowel dysfunction, impacting millions. Their SNM therapy has shown clinical proof in reducing symptoms, enhancing quality of life. The company boasts the first long-lived rechargeable SNM system and has extensive reimbursement coverage in the U.S. and Europe. More details available on their website.

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will participate in the virtual SVB Leerink Global Healthcare Conference on February 24, 2021.

Axonics’ management team is scheduled to present at 11:20 a.m. Eastern Time. Interested parties may access the live and archived webcast of the presentation by visiting the Axonics investor relations website.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. Axonics SNM therapy, which has been clinically proven to reduce symptoms and restore pelvic floor function, is now being offered at hundreds of medical centers across the U.S. and in dozens of select hospitals in Western Europe. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. The Axonics System is the first long-lived rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit www.axonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210211005196/en/

FAQ

When will Axonics present at the SVB Leerink Global Healthcare Conference?

Axonics will present at the virtual SVB Leerink Global Healthcare Conference on February 24, 2021, at 11:20 a.m. Eastern Time.

What is Axonics Modulation Technologies known for?

Axonics Modulation Technologies is known for developing implantable sacral neuromodulation devices that treat urinary and bowel dysfunction.

How many adults are affected by overactive bladder according to Axonics?

Axonics estimates that overactive bladder affects approximately 87 million adults in the U.S. and Europe.

Is Axonics' SNM therapy clinically proven?

Yes, Axonics' SNM therapy is clinically proven to reduce symptoms of urinary and bowel dysfunction and restore pelvic floor function.

What is unique about the Axonics System?

The Axonics System is the first long-lived rechargeable sacral neuromodulation system approved for sale worldwide and the first with full-body MRI conditional labeling.

Where can I find more information about Axonics?

More information about Axonics can be found on their website.